Diagnos Inc (TSE:ADK) has released an update.
Diagnos Inc., a Canadian company specializing in early detection of health issues with AI technology, has awarded 250,000 stock options to new board director Mr. Michael Braeuel, with a vesting period of 50% per year and an exercise price set at $0.28 per share. These options, granted on March 4, 2024, are exercisable until March 4, 2029, marking a significant corporate governance event for investors.
For further insights into TSE:ADK stock, check out TipRanks’ Stock Analysis page.
